Clinical Diagnostics Insider

(formerly Diagnostic Testing and Emerging Technologies)

Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies

AI in Health Care: Balancing Benefits and Barriers

By Michael Schubert, PhD | Oct 30, 2024 | 1 min read

AI can help alleviate the burden on clinical labs—but only with sufficient investment, enthusiasm, and understanding

Background photo showing medical record changing from paperwork to electronic medical record.

Esophageal Pre-Cancer Testing Gaining Greater Traction

By Ron Shinkman | Oct 29, 2024 | 1 min read

How three companies are addressing screening challenges with tests that help improve chances of early detection

An elderly male patient holds a hand to his throat as he speaks with his doctor, illustrating the concept of throat problems and potential esophageal cancer.

Computing the Future of the Lab

By Michael Schubert, PhD | Oct 28, 2024 | 1 min read

Computational biology expert Keaun Amani shares his advice and insights on AI and machine learning tools for the clinical lab

neuron 3D illustration, illustrating convolutional neural networks concept.

Lab Companies Scramble to Bring Coronavirus Detection Tests to Market

By Glenn S. Demby | Jan 30, 2020 | 1 min read

...

This content is for Paid Members only.
Register

Already a member? Log in here

Doing What We’ve Always Done

By Glenn S. Demby | Jan 27, 2020 | 1 min read

...

This content is for Paid Members only.
Register

Already a member? Log in here

Test Quality: New Study Casts Doubt on Whole Exome Sequencing’s Accuracy in Diagnosing Genetic Disorders

By Glenn S. Demby | Jan 24, 2020 | 1 min read

Depending on the reporting laboratory, patients who undergo whole exome sequencing may receive false negatives or incomplete test results. That is the finding of a new study published in Clinical Chemistry

FDA Watch: Agency Exempts Dozens of Tests from 510(k) Review

By Glenn S. Demby | Jan 24, 2020 | 1 min read

On Dec. 30, 2019, the U.S. Food and Drug Administration (FDA) published a final order exempting dozens of Class I and Class II medical devices that previously required 510(k) submission from 510(k) premarket review